» Articles » PMID: 32827564

Simultaneous Splenectomy Improves Outcomes After Adult Living Donor Liver Transplantation

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2020 Aug 23
PMID 32827564
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Small-for-size graft (SFSG) syndrome is a major cause of graft loss after living donor liver transplantation (LDLT). Splenectomy (Spx) is an option to prevent this catastrophic complication, but its effect remains controversial. Herein, we aimed to elucidate the effect of simultaneous Spx on graft function and long-term outcomes after LDLT.

Methods: Three hundred and twenty patients were divided into 2 groups: those undergoing (n = 258) and those not undergoing (n = 62) simultaneous Spx. To overcome selection bias, propensity score matching (PSM) was performed (n = 50 in each group).

Results: Before PSM, recipients undergoing simultaneous Spx showed better graft function on post-operative day (POD) 7 and 14, as well as lower sepsis frequency within 6 months after LDLT and better graft survival rates compared to those not undergoing Spx. After PSM, compared to patients not undergoing Spx, those undergoing Spx had a lower frequency of early graft dysfunction on POD 7 (p = 0.04); a lower frequency of SFSG syndrome (p = 0.01), lower serum total bilirubin levels (p = 0.001), and lower international normalized ratio (p = 0.004) on POD 14; lower sepsis frequency within 6 months after LDLT (p = 0.02), and better graft survival rates (p = 0.04). Univariate analysis revealed that not undergoing Spx (hazard ratio 3.06; 95% CI 1.07-11.0; p = 0.037) was the only risk factor for graft loss after LDLT.

Conclusions: Simultaneous Spx may prevent SFSG syndrome and is a predictive factor for graft survival after LDLT. Simultaneous Spx is recommended when a small graft (≤35% of standard liver weight) is predicted preoperatively, or for patients with portal hypertension or high portal pressure (above 20 mmHg) after reperfusion in LDLT.

Lay Summary: Living donor liver transplantation (LDLT) for patients with acute or chronic liver failure is an alternative to overcome the deceased donor shortage. The potential mismatch between graft and body size is a problem that needs to be solved for LDLT recipients. Herein, we evaluated the impact of simultaneous splenectomy and showed that it was associated with favorable outcomes in patients undergoing LDLT.

Citing Articles

Indications and recipient outcomes of adult left lobe living donor liver transplantation.

Hibi T Updates Surg. 2025; .

PMID: 39888547 DOI: 10.1007/s13304-024-02050-8.


Living Donor Liver Transplantation with Small Left Lobe Grafts: Prospective Validation of Utility of Splenectomy in Selected Recipients.

Matsushima H, Soyama A, Hara T, Hamada T, Kawaguchi Y, Migita K Ann Transplant. 2025; 30():e946374.

PMID: 39806794 PMC: 11742235. DOI: 10.12659/AOT.946374.


Clinical validation of preoperative serum markers for liver fibrosis in living donor liver transplantation recipients.

Tomino T, Itoh S, Toshima T, Yoshiya S, Bekki Y, Iseda N Surg Today. 2024; .

PMID: 39317845 DOI: 10.1007/s00595-024-02941-8.


Multivariable linear model for predicting graft weight based on 3-dimensional volumetry in regards to body weight change of living liver donor: an observational cohort study.

Han S, Rhu J, Lim S, Choi G, Kim J, Joh J Ann Surg Treat Res. 2024; 107(2):91-99.

PMID: 39139829 PMC: 11317358. DOI: 10.4174/astr.2024.107.2.91.


Immunology of simultaneous liver and kidney transplants with identification and prevention of rejection.

Parajuli S, Hidalgo L, Foley D Front Transplant. 2024; 1:991546.

PMID: 38994375 PMC: 11235231. DOI: 10.3389/frtra.2022.991546.